stoxline Quote Chart Rank Option Currency Glossary
X4 Pharmaceuticals, Inc. (XFOR)
0.9656  -0.026 (-2.66%)    06-18 16:00
Open: 0.9866
High: 1.015
Volume: 942,927
Pre. Close: 0.992
Low: 0.9548
Market Cap: 162(M)
Technical analysis
2024-06-18 4:49:54 PM
Short term     
Mid term     
Targets 6-month :  1.19 1-year :  1.31
Resists First :  1.02 Second :  1.12
Pivot price 1.02
Supports First :  0.86 Second :  0.71
MAs MA(5) :  1.02 MA(20) :  0.99
MA(100) :  1.05 MA(250) :  1.09
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  42.5 D(3) :  58.5
RSI RSI(14): 43.1
52-week High :  2.05 Low :  0.57
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ XFOR ] has closed above bottom band by 18.6%. Bollinger Bands are 44.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.02 - 1.02 1.02 - 1.03
Low: 0.94 - 0.95 0.95 - 0.95
Close: 0.95 - 0.97 0.97 - 0.97
Company Description

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was founded in 2010 and is headquartered in Boston, Massachusetts.

Headline News

Mon, 17 Jun 2024
Kingdon Capital Management L.L.C. Raises Stock Position in X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) - MarketBeat

Wed, 08 May 2024
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q1 2024 Earnings Call Transcript - Yahoo Finance

Tue, 30 Apr 2024
X4 Pharmaceuticals to Report First-Quarter 2024 Financial Results and Host a Conference Call and Webcast on May 7 ... - GlobeNewswire

Tue, 30 Apr 2024
48% Of This X4 Pharmaceuticals Insider's Holdings Were Sold - Simply Wall St

Mon, 29 Apr 2024
X4 Pharmaceuticals: XOLREMDI FDA Approval and Launch Update - - TipRanks

Mon, 29 Apr 2024
X4 Pharmaceuticals Launches XOLREMDI with FDA Approval - - TipRanks

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 168 (M)
Shares Float 128 (M)
Held by Insiders 0.9 (%)
Held by Institutions 67.5 (%)
Shares Short 12,210 (K)
Shares Short P.Month 12,260 (K)
Stock Financials
EPS -0.68
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -61.1 %
Return on Equity (ttm) -489.2 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -0.69
Qtrly Earnings Growth 0 %
Operating Cash Flow -104 (M)
Levered Free Cash Flow -63 (M)
Stock Valuations
PE Ratio -1.45
PEG Ratio 0
Price to Book value 96.56
Price to Sales 0
Price to Cash Flow -1.57
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android